marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-14-2024
Cara Therapeutics Balance Sheet 2011-2024 | CARA
Annual Balance Sheet Cara Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-9.78 M | -26.4 M | -14 M | -15.1 M | -9.39 M | -12.1 M | -15.1 M | -52.7 M | -12.4 M | -337 K | -3.34 M | ||
Long Term Debt |
6.09 M | - | 1.92 M | 3.67 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 1.92 M | 1.76 M | 1.6 M | 967 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 3.35 M | 16.7 M | 1.72 M | 1.57 M | 585 K | 874 K | 1.14 M | 1.41 M | 1.65 M |
Total Current Liabilities |
25.6 M | 23.5 M | 17.6 M | 18.5 M | 42.9 M | 40.4 M | 8.51 M | 11.5 M | 5.27 M | 3.4 M | - | - | - |
Total Liabilities |
68.8 M | 23.5 M | - | - | 46.2 M | 57.2 M | 10.2 M | 13.1 M | 5.85 M | 4.27 M | 6.57 M | 3.1 M | 4.58 M |
Deferred Revenue |
- | - | - | - | 22.3 M | 26.8 M | - | - | - | 1.45 M | 3.48 M | - | - |
Retained Earnings |
-685 M | -566 M | -481 M | -392 M | -401 M | -294 M | -220 M | -162 M | -105 M | -80.2 M | -62.5 M | -59.4 M | -53.1 M |
Total Assets |
126 M | 182 M | 247 M | 271 M | 233 M | 191 M | 97 M | 63.8 M | 111 M | 55.9 M | 18.1 M | 5.54 M | 10.7 M |
Cash and Cash Equivalents |
51.8 M | 63.7 M | 13.9 M | 32.1 M | 18.3 M | 15.1 M | 9.39 M | 12.1 M | 15.1 M | 52.7 M | 12.4 M | 1.12 M | - |
Book Value |
57.1 M | 159 M | 247 M | 271 M | 187 M | 134 M | 86.8 M | 50.7 M | 105 M | 51.7 M | 11.5 M | 2.44 M | 6.1 M |
Total Shareholders Equity |
57.1 M | 159 M | 228 M | 249 M | 187 M | 134 M | 86.8 M | 50.7 M | 105 M | 51.7 M | -54.1 M | -58.1 M | - |
All numbers in USD currency
Quarterly Balance Sheet Cara Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 7.32 M | 6.82 M | 6.09 M | 6.82 M | - | - | - | 497 K | 983 K | 1.46 M | 1.92 M | 2.37 M | 2.82 M | 3.25 M | 3.67 M | 3.67 M | 3.67 M | 3.67 M | 3.35 M | 3.35 M | 3.35 M | 3.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
50.6 M | 60.9 M | 60.3 M | 68.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 511 K | 9.77 M | 14.2 M | 22.3 M | 22.3 M | 22.3 M | 22.3 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | - | - | - | - | - | - | - | - | - | - | 89 K | 963 K | 1.45 M | 1.45 M | 1.45 M | 1.45 M | 3.48 M | 3.48 M | 3.48 M | 3.48 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-748 M | -735 M | -715 M | -685 M | -652 M | -624 M | -593 M | -566 M | -536 M | -513 M | -509 M | -481 M | -447 M | -446 M | -416 M | -392 M | -392 M | -392 M | -392 M | -401 M | -401 M | -401 M | -401 M | -294 M | -294 M | -294 M | -294 M | -220 M | -220 M | -220 M | -220 M | -162 M | -162 M | -162 M | -162 M | -105 M | -105 M | -105 M | -105 M | -80.2 M | -80.2 M | -80.2 M | -80.2 M | -62.5 M | -62.5 M | -62.5 M | -62.5 M | - | - | - | - | - | - | - | - |
Total Assets |
51.3 M | 72.5 M | 90.1 M | 126 M | 115 M | 134 M | 153 M | 182 M | 214 M | 227 M | 224 M | 247 M | 225 M | 221 M | 250 M | 271 M | 271 M | 271 M | 271 M | 233 M | 233 M | 233 M | 233 M | 191 M | 191 M | 191 M | 191 M | 97 M | 97 M | 97 M | 97 M | 63.8 M | 63.8 M | 63.8 M | 63.8 M | 111 M | 111 M | 111 M | 111 M | 55.9 M | 55.9 M | 55.9 M | 55.9 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
37.1 M | 49.2 M | 47 M | 51.8 M | 64.8 M | 60.2 M | 47.8 M | 63.7 M | 43.2 M | 47.1 M | 21.8 M | 13.5 M | 23.4 M | 22.7 M | 22.5 M | 32.1 M | 31.7 M | 31.7 M | 31.7 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 9.39 M | 9.39 M | 9.39 M | 9.39 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 52.7 M | 52.7 M | 52.7 M | 52.7 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 1.12 M | - | - | - | 4.1 M | - | - | - |
Book Value |
707 K | 11.6 M | 29.8 M | 57.1 M | 115 M | 134 M | 153 M | 182 M | 214 M | 227 M | 224 M | 247 M | 225 M | 221 M | 250 M | 271 M | 271 M | 271 M | 271 M | 233 M | 233 M | 233 M | 233 M | 191 M | 191 M | 191 M | 191 M | 97 M | 97 M | 97 M | 97 M | 63.8 M | 63.8 M | 63.8 M | 63.8 M | 111 M | 111 M | 111 M | 111 M | 55.9 M | 55.9 M | 55.9 M | 55.9 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
707 K | 11.6 M | 29.8 M | 57.1 M | 85.6 M | 109 M | 137 M | 159 M | 185 M | 204 M | 204 M | 228 M | 207 M | 203 M | 230 M | 249 M | 249 M | 249 M | 249 M | 187 M | 187 M | 187 M | 187 M | 134 M | 134 M | 134 M | 134 M | 86.8 M | 86.8 M | 86.8 M | 86.8 M | 50.7 M | 50.7 M | 50.7 M | 50.7 M | 105 M | 105 M | 105 M | 105 M | 51.7 M | 51.7 M | 51.7 M | 51.7 M | -54.1 M | -54.1 M | -54.1 M | -54.1 M | -58.1 M | - | - | - | -52.1 M | - | - | - |
All numbers in USD currency